camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - inne preparaty nasercowe - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
durogesic 25 mcg/h system transdermalny
janssen-cilag international n.v. - fentanylum - system transdermalny - 25 mcg/h
durogesic 50 mcg/h system transdermalny
janssen-cilag international n.v. - fentanylum - system transdermalny - 50 mcg/h
durogesic 75 mcg/h system transdermalny
janssen-cilag international n.v. - fentanylum - system transdermalny - 75 mcg/h
durogesic 100 mcg/h system transdermalny
janssen-cilag international n.v. - fentanylum - system transdermalny - 100 mcg/h
durogesic 12 mcg/h system transdermalny
janssen-cilag international n.v. - fentanylum - system transdermalny - 12 mcg/h
fentanyl actavis 25 μg/h system transdermalny, plaster
actavis group ptc ehf. - fentanylum - system transdermalny, plaster - 25 μg/h
fentanyl actavis 75 μg/h system transdermalny, plaster
actavis group ptc ehf. - fentanylum - system transdermalny, plaster - 75 μg/h
fentanyl actavis 100 mcg/h system transdermalny, plaster
actavis group ptc ehf. - fentanylum - system transdermalny, plaster - 100 mcg/h
fenta mx 25 25 mcg/h system transdermalny, plaster
sandoz gmbh - fentanylum - system transdermalny, plaster - 25 mcg/h